Study protocol for a two-site clinical trial to validate a smartphone-based artificial intelligence classifier identifying cervical precancer and cancer in HPV-positive women in Cameroon

Inès Baleydier, Pierre Vassilakos, Roser Viñals, Ania Wisniak, Bruno Kenfack, Jovanny Tsuala Fouogue, George Enownchong Enow Orock, Sophie Lemoupa Makajio, Evelyn Foguem Tincho, Manuela Undurraga, Magali Cattin, Solomzi Makohliso, Klaus Schönenberger, Alain Gervaix, Jean-Philippe Thiran and Patrick Petignat

PLOS ONE, 2021, vol. 16, issue 12, 1-13

Abstract: Introduction: Cervical cancer remains a major public health challenge in low- and middle-income countries (LMICs) due to financial and logistical issues. WHO recommendation for cervical cancer screening in LMICs includes HPV testing as primary screening followed by visual inspection with acetic acid (VIA) and treatment. However, VIA is a subjective procedure dependent on the healthcare provider’s experience. Its accuracy can be improved by computer-aided detection techniques. Our aim is to assess the performance of a smartphone-based Automated VIA Classifier (AVC) relying on Artificial Intelligence to discriminate precancerous and cancerous lesions from normal cervical tissue. Methods: The AVC study will be nested in an ongoing cervical cancer screening program called “3T-study” (for Test, Triage and Treat), including HPV self-sampling followed by VIA triage and treatment if needed. After application of acetic acid on the cervix, precancerous and cancerous cells whiten more rapidly than non-cancerous ones and their whiteness persists stronger overtime. The AVC relies on this key feature to determine whether the cervix is suspect for precancer or cancer. In order to train and validate the AVC, 6000 women aged 30 to 49 years meeting the inclusion criteria will be recruited on a voluntary basis, with an estimated 100 CIN2+, calculated using a confidence level of 95% and an estimated sensitivity of 90% +/-7% precision on either side. Diagnostic test performance of AVC test and two current standard tests (VIA and cytology) used routinely for triage will be evaluated and compared. Histopathological examination will serve as reference standard. Participants’ and providers’ acceptability of the technology will also be assessed. The study protocol was registered under ClinicalTrials.gov (number NCT04859530). Expected results: The study will determine whether AVC test can be an effective method for cervical cancer screening in LMICs.

Date: 2021
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0260776 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 60776&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0260776

DOI: 10.1371/journal.pone.0260776

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().